Search results
Results from the WOW.Com Content Network
Mycobacterium avium-intracellulare infection (MAI) is an atypical mycobacterial infection, i.e. one with nontuberculous mycobacteria or NTM, caused by Mycobacterium avium complex (MAC), which is made of two Mycobacterium species, M. avium and M. intracellulare. [1]
Amikacin is an antibiotic medication used for a number of bacterial infections. [9] This includes joint infections, intra-abdominal infections, meningitis, pneumonia, sepsis, and urinary tract infections. [9] It is also used for the treatment of multidrug-resistant tuberculosis. [10] It is used by injection into a vein using an IV or into a ...
Evidence is insufficient to support its use in other conditions [1] though a retrospective study found it 95% effective in the treatment of Mycobacterium avium complex (MAC) when administered with a macrolide and ethambutol, [3] as well as the drugs amikacin and clarithromycin. [4]
However, these classifications are based on laboratory behavior. The development of antibiotics has had a profound effect on the health of people for many years. Also, both people and animals have used antibiotics to treat infections and diseases. In practice, both treat bacterial infections. [1]
Alternatives to fosfomycin include nitrofurantoin, pivmecillinam, and co-amoxiclav in oral treatment of urinary-tract infections associated with extended-spectrum beta-lactamase. [ 48 ] In a separate study, CRE were treated with colistin , amikacin , and tigecycline, and emphasizes the importance of using gentamicin in patients undergoing ...
These bacteria cause Mycobacterium avium-intracellulare infections or Mycobacterium avium complex infections in humans. [2] These bacteria are common and are found in fresh and salt water, in household dust and in soil. [3] MAC bacteria usually cause infection in those who are immunocompromised or those with severe lung disease.
The proposed empirical treatment approach includes antibiotics such as amikacin, clarithromycin, or rifabutin, taking into consideration reported resistance to doxycycline and minocycline. Combination therapy is commonly advocated to minimize the risk of resistance development, aligning with established practices in managing mycobacterial ...
Terminal complement pathway deficiency is a genetic condition affecting the complement membrane attack complex (MAC). It involves deficiencies of C5, C6, C7, and C8. (While C9 is part of the MAC, and deficiencies have been identified, [1] it is not required for cell lysis. [2]) People with this condition are prone to meningococcal infection. [3]